Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025

Core Insights - Leap Therapeutics, Inc. announced the presentation of final clinical results from Part B of the DeFianCe study, focusing on the efficacy of sirexatamab (DKN-01) in combination with bevacizumab and chemotherapy for advanced microsatellite stable colorectal cancer [1][2] Company Overview - Leap Therapeutics is a biotechnology company specializing in targeted and immuno-oncology therapeutics, with a pipeline that includes sirexatamab (DKN-01) and FL-501, both humanized monoclonal antibodies targeting specific proteins [2] Clinical Study Details - The DeFianCe study is a Phase 2 trial comparing the Sirexatamab Arm (sirexatamab plus bevacizumab and chemotherapy) to the Control Arm (bevacizumab and chemotherapy) in patients who have received one prior systemic therapy for advanced disease [1][2] - The final results will be presented at the European Society for Medical Oncology (ESMO) Congress 2025, scheduled for October 17-21 in Berlin, Germany [1]